PURPOSE: sPLA2-IIa is a biomarker for many inflammatory diseases in humans and is found at high levels in human tears. However, its role in ocular surface inflammation remains unclear. An experimentally induced BALB/c mouse dry eye (DE) model was used to elucidate the role of sPLA2-IIa in ocular surface inflammation. METHODS: BALB/c mice were subcutaneously injected with scopolamine and placed in a daytime air-drying device for 5 to 10 days. Control mice received no treatment. DE status was evaluated with tear production with a phenol-red thread method. Tear inflammatory cytokines were quantified by multiplex immunoassays. Ocular surface inflammation and sPLA2-IIa expression were examined by immune-staining and quantitative (q)RT(2)-PCR. Conjunctiva (CNJ) of the mice was cultured for prostaglandin E2 production induced by sPLA2-IIa with various amount of sPLA2-IIa inhibitor, S-3319. RESULTS: Treated mice produced fewer tears and heavier corneal (CN) fluorescein staining than the untreated controls (P < 0.001). They also revealed lower goblet cell density (P < 0.001) with greater inflammatory cell infiltration within the conjunctiva, and higher concentration of tear inflammatory cytokines than the controls. Moreover, treated mice showed heavier sPLA2-IIa immune staining than the controls in the CNJ epithelium, but not in the CN epithelium or the lacrimal gland. Treated mice exhibited upregulated sPLA2-IIa and cytokine gene transcription. Furthermore, CNJ cultures treated with sPLA2-IIa inhibitor showed significantly reduced sPLA2-IIa-induced inflammation. CONCLUSIONS: This is the first report regarding sPLA2-IIa in the regulation of ocular surface inflammation. The findings may therefore lead to new therapeutic strategies for ocular surface inflammation, such as DE disease.
PURPOSE:sPLA2-IIa is a biomarker for many inflammatory diseases in humans and is found at high levels in human tears. However, its role in ocular surface inflammation remains unclear. An experimentally induced BALB/c mousedry eye (DE) model was used to elucidate the role of sPLA2-IIa in ocular surface inflammation. METHODS: BALB/c mice were subcutaneously injected with scopolamine and placed in a daytime air-drying device for 5 to 10 days. Control mice received no treatment. DE status was evaluated with tear production with a phenol-red thread method. Tear inflammatory cytokines were quantified by multiplex immunoassays. Ocular surface inflammation and sPLA2-IIa expression were examined by immune-staining and quantitative (q)RT(2)-PCR. Conjunctiva (CNJ) of the mice was cultured for prostaglandin E2 production induced by sPLA2-IIa with various amount of sPLA2-IIa inhibitor, S-3319. RESULTS: Treated mice produced fewer tears and heavier corneal (CN) fluorescein staining than the untreated controls (P < 0.001). They also revealed lower goblet cell density (P < 0.001) with greater inflammatory cell infiltration within the conjunctiva, and higher concentration of tear inflammatory cytokines than the controls. Moreover, treated mice showed heavier sPLA2-IIa immune staining than the controls in the CNJ epithelium, but not in the CN epithelium or the lacrimal gland. Treated mice exhibited upregulated sPLA2-IIa and cytokine gene transcription. Furthermore, CNJ cultures treated with sPLA2-IIa inhibitor showed significantly reduced sPLA2-IIa-induced inflammation. CONCLUSIONS: This is the first report regarding sPLA2-IIa in the regulation of ocular surface inflammation. The findings may therefore lead to new therapeutic strategies for ocular surface inflammation, such as DE disease.
Authors: Kyung-Chul Yoon; Cintia S De Paiva; Hong Qi; Zhuo Chen; William J Farley; De-Quan Li; Michael E Stern; Stephen C Pflugfelder Journal: J Autoimmun Date: 2007-11-07 Impact factor: 7.094
Authors: R J A Fijneman; J R Peham; M A van de Wiel; G A Meijer; I Matise; A Velcich; R T Cormier Journal: Cancer Sci Date: 2008-11 Impact factor: 6.716
Authors: Tuomas Mirtti; Veli Jukka O Laine; Heikki Hiekkanen; Saija Hurme; Outi Rowe; Timo J Nevalainen; Markku Kallajoki; Kalle Alanen Journal: APMIS Date: 2009-03 Impact factor: 3.205
Authors: Ferdinando Mannello; Wenyi Qin; Weizhu Zhu; Laura Fabbri; Gaetana A Tonti; Edward R Sauter Journal: Breast Cancer Res Treat Date: 2007-10-12 Impact factor: 4.872
Authors: Kathy Jaworski; Maryam Ahmadian; Robin E Duncan; Eszter Sarkadi-Nagy; Krista A Varady; Marc K Hellerstein; Hui-Young Lee; Varman T Samuel; Gerald I Shulman; Kee-Hong Kim; Sarah de Val; Chulho Kang; Hei Sook Sul Journal: Nat Med Date: 2009-01-11 Impact factor: 53.440
Authors: Srihari Narayanan; Rachel L Redfern; William L Miller; Kelly K Nichols; Alison M McDermott Journal: Ocul Surf Date: 2013-01-29 Impact factor: 5.033
Authors: Sin Man Lam; Louis Tong; Xinrui Duan; U Rajendra Acharya; Jen Hong Tan; Andrea Petznick; Markus R Wenk; Guanghou Shui Journal: J Lipid Res Date: 2014-07-03 Impact factor: 5.922
Authors: Rachel L Redfern; Nimesh Patel; Samuel Hanlon; William Farley; Margaret Gondo; Stephen C Pflugfelder; Alison M McDermott Journal: Invest Ophthalmol Vis Sci Date: 2013-02-28 Impact factor: 4.799
Authors: Monique D Courtenay; William Cade; Stephen G Schwartz; Jaclyn L Kovach; Anita Agarwal; Gaofeng Wang; Jonathan L Haines; Margaret A Pericak-Vance; Wiliam K Scott Journal: Invest Ophthalmol Vis Sci Date: 2014-07-11 Impact factor: 4.799